HR 64, the Patients First Act of 2019, bolsters the use of stem cell research to better understand and treat diseases and other adverse health conditions. This Act, which has been introduced in every congressional session since 2007, calls to enhance research efforts, advance human clinical trials using “ethically obtained” stem cells, and boost pluripotent (i.e. non-human embryo derived) stem cells for research purposes.
The use of stem cells in research has a long and controversial history. Recently, the National Institutes of Health (NIH) was pressured to block the use of fetal tissue derived stem cells in research. However, the NIH and affiliated researchers argue that the use of these stem cells in research is a valuable tool.
We previously published a brief on the Patients First Act of 2017 (HR 2918 / S 2956, 115th Congress), the version introduced in the 115th Congress.